Stereotactic body radiotherapy for prostate cancer

Clinical Oncology

Volumn 27, Issue 5, 2015, Pages 270-279

  Henderson, D R ^a   Tree, A C ^a   van As, N J ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Hypofractionation; Image guided radiotherapy; Intrafraction motion; Oligometastatic; Prostate cancer; Stereotactic radiotherapy

Indexed keywords

ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER CONTROL; CANCER GROWTH; CANCER RADIOTHERAPY; EVIDENCE BASED PRACTICE; FOLLOW UP; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; STEREOTACTIC BODY RADIATION THERAPY; TOMOTHERAPY; PROCEDURES; PROSTATIC NEOPLASMS; RADIOSURGERY;

DOSE FRACTIONATION; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIOSURGERY; RADIOTHERAPY, INTENSITY-MODULATED;

EID: 84933280156     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2015.01.011     Document Type: Article

References (77)

1. UK DoH. Radiotherapy Services in England 2012: Available from: . https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/213151/Radiotherapy-Services-in-England-2012.pdf.
2. CRUK. Prostate cancer - UK incidence statistics. [accessed 29.09.14].
3. Buyyounouski M.K., Price R.A., Harris E.E., et al. Stereotactic body radiotherapy for primary management of early-stage, low- to intermediate-risk prostate cancer: report of the American Society for Therapeutic Radiology and Oncology Emerging Technology Committee. Int J Radiat Oncol Biol Phys 2010 Apr, 76(5):1297-1304.
4. ASTRO Model policies: stereotactic body radiotherapy 16/09/2014, Available from:. https://www.astro.org/uploadedFiles/Main_Site/Practice:Management/Reimbursement/2013HPcoding%20guidelines_SBRT_Final.pdf.
5. NCCN Clinical practice guidelines in oncology 2014, [16/09/2014], Available from:. http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.
6. Dasu A., Toma-Dasu I. Prostate alpha/beta revisited - an analysis of clinical results from 14 168 patients. Acta Oncol 2012 Nov, 51(8):963-974.
7. Miralbell R., Roberts S.A., Zubizarreta E., Hendry J.H. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: alpha/beta = 1.4 (0.9-2.2) Gy. Int J Radiat Oncol Biol Phys 2011 Feb 14, 82(1):e17-e24.
8. Marzi S., Saracino B., Petrongari M.G., et al. Modeling of alpha/beta for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer. JExp Clin Cancer Res 2009, 28:117.
9. Tucker S.L., Thames H.D., Michalski J.M., et al. Estimation of alpha/beta for Late Rectal Toxicity Based on RTOG 94-06. Int J Radiat Oncol Biol Phys 2011 Mar 4, 81(2):600-605.
10. Cabrera A.R., Lee W.R. Hypofractionation for clinically localized prostate cancer. Semin Radiat Oncol 2013 Jul, 23(3):191-197.
11. Tree A.C., Khoo V.S., van As N.J., Partridge M. Is biochemical relapse-free survival after profoundly hypofractionated radiotherapy consistent with current radiobiological models?. Clin Oncol (R Coll Radiol) 2014 Apr, 26(4):216-229.
12. Kirkpatrick J.P., Meyer J.J., Marks L.B. The linear-quadratic model is inappropriate to model high dose per fraction effects in radiosurgery. Semin Radiat Oncol 2008 Oct, 18(4):240-243.
13. Brenner D.J. The linear-quadratic model is an appropriate methodology for determining isoeffective doses at large doses per fraction. Semin Radiat Oncol 2008 Oct, 18(4):234-239.
14. Dearnaley D.P., Jovic G., Syndikus I., et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet Oncol 2014 Apr, 15(4):464-473.
15. Tree A.C., Alexander E.J., Van As N.J., Dearnaley D.P., Khoo V. Biological dose escalation and hypofractionation: what is there to be gained and how will it best be done?. Clin Oncol (R Coll Radiol) 2013 Aug, 25(8):483-498.
16. Dearnaley D., Syndikus I., Sumo G., et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol 2012 Jan, 13(1):43-54.
17. Sullivan R., Peppercorn J., Sikora K., et al. Delivering affordable cancer care in high-income countries. Lancet Oncol 2011 Sep, 12(10):933-980.
18. Yu J.B., Cramer L.D., Herrin J., Soulos P.R., Potosky A.L., Gross C.P. Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: comparison of toxicity. JClin Oncol 2014 Apr 20, 32(12):1195-1201.
19. Hodges J.C., Lotan Y., Boike T.P., Benton R., Barrier A., Timmerman R.D. Cost-effectiveness analysis of SBRT versus IMRT: an emerging initial radiation treatment option for organ-confined prostate cancer. Am J Manag Care 2012 May, 18(5):e186-e193.
20. Sher D.J., Parikh R.B., Mays-Jackson S., Punglia R.S. Cost-effectiveness Analysis of SBRT Versus IMRT for Low-risk Prostate Cancer. Am J Clin Oncol 2014 Jun, 37(3):215-221.
21. Collins C.D., Lloyd-Davies R.W., Swan A.V. Radical external beam radiotherapy for localised carcinoma of the prostate using a hypofractionation technique. Clin Oncol (R Coll Radiol) 1991 May, 3(3):127-132.
22. Collins C.D. Radical external beam radiotherapy for localized carcinoma of the prostate using a hypofractionation technique. Clin Oncol (R Coll Radiol) 1991 Nov, 3(6):358.
23. King C.R., Freeman D., Kaplan I., et al. Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiother Oncol 2013 Nov, 109(2):217-221.
24. Kilby W., Dooley J.R., Kuduvalli G., Sayeh S., Maurer C.R. The CyberKnife Robotic Radiosurgery System in 2010. Technol Cancer Res Treat 2010 Oct, 9(5):433-452.
25. Loblaw A., Cheung P., D'Alimonte L., et al. Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: toxicity, biochemical, and pathological outcomes. Radiother Oncol 2013 May, 107(2):153-158.
26. Madsen B.L., Hsi R.A., Pham H.T., Fowler J.F., Esagui L., Corman J. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys 2007 Mar 15, 67(4):1099-1105.
27. Boike T.P., Lotan Y., Cho L.C., et al. Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer. JClin Oncol 2011 May 20, 29(15):2020-2026.
28. Macdougall N.D., Dean C., Muirhead R. Stereotactic body radiotherapy in prostate cancer: is rapidarc a better solution than cyberknife?. Clin Oncol (R Coll Radiol) 2014 Jan, 26(1):4-9.
29. Murray L.J., Cosgrove V., Lilley J., et al. Developing a class solution for Prostate Stereotactic Ablative Body Radiotherapy (SABR) using Volumetric Modulated Arc Therapy (VMAT). Radiother Oncol 2014 Feb, 110(2):298-302.
30. Alongi F., Cozzi L., Arcangeli S., et al. Linac based SBRT for prostate cancer in 5 fractions with VMAT and flattening filter free beams: preliminary report of a phase II study. Radiat Oncol 2013 Jul 8, 8(1):171.
31. Moseley D.J., White E.A., Wiltshire K.L., et al. Comparison of localization performance with implanted fiducial markers and cone-beam computed tomography for on-line image-guided radiotherapy of the prostate. Int J Radiat Oncol Biol Phys 2007 Mar 1, 67(3):942-953.
32. Maund I.F., Benson R.J., Fairfoul J., Cook J., Huddart R., Poynter A. Image-guided radiotherapy of the prostate using daily CBCT: the feasibility and likely benefit of implementing a margin reduction. Br J Radiol 2014 Dec, 87(1044):20140459.
33. Barney B.M., Lee R.J., Handrahan D., Welsh K.T., Cook J.T., Sause W.T. Image-guided radiotherapy (IGRT) for prostate cancer comparing kV imaging of fiducial markers with cone beam computed tomography (CBCT). Int J Radiat Oncol Biol Phys 2011 May 1, 80(1):301-305.
34. Shi W., Li J.G., Zlotecki R.A., et al. Evaluation of kV cone-beam ct performance for prostate IGRT: a comparison of automatic grey-value alignment to implanted fiducial-marker alignment. Am J Clin Oncol 2011 Feb, 34(1):16-21.
35. Deegan T., Owen R., Holt T., et al. Assessment of cone beam CT registration for prostate radiation therapy: Fiducial marker and soft tissue methods. JMed Imaging Radiat Oncol 2014 Jun 22, 59(1):91-98.
36. Bolzicco G., Favretto M.S., Satariano N., Scremin E., Tambone C., Tasca A. Asingle-center study of 100 consecutive patients with localized prostate cancer treated with stereotactic body radiotherapy. BMC Urol 2013, 13:49.
37. King C.R., Brooks J.D., Gill H., Presti J.C. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys 2011 Feb 5, 82(2):877-882.
38. Katz A.J., Santoro M., Diblasio F., Ashley R. Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years. Radiat Oncol 2013 May 13, 8(1):118.
39. Oliai C., Lanciano R., Sprandio B., et al. Stereotactic body radiation therapy for the primary treatment of localized prostate cancer. JRadiat Oncol 2013 Mar, 2(1):63-70.
40. McNair H.A., Welake L., Lips I.M., Andreyev J., Van Vulpen M., Dearnaley D.P. Asystematic review: Effectiveness of rectal emptying preparation in prostate cancer patients. Practical Radiation Oncology 2014, 4(6):437-447.
41. Smitsmans M.H., Pos F.J., de Bois J., et al. The influence of a dietary protocol on cone beam CT-guided radiotherapy for prostate cancer patients. Int J Radiat Oncol Biol Phys 2008 Jul 15, 71(4):1279-1286.
42. Yahya S., Zarkar A., Southgate E., Nightingale P., Webster G. Which bowel preparation is best? Comparison of a high-fibre diet leaflet, daily microenema and no preparation in prostate cancer patients treated with radical radiotherapy to assess the effect on planned target volume shifts due to rectal distension. Br J Radiol 2013 Nov, 86(1031):20130457.
43. Azcona J.D., Xing L., Chen X., Bush K., Li R. Assessing the dosimetric impact of real-time prostate motion during volumetric modulated arc therapy. Int J Radiat Oncol Biol Phys 2014 Apr 1, 88(5):1167-1174.
44. Kupelian P., Willoughby T., Mahadevan A., et al. Multi-institutional clinical experience with the Calypso System in localization and continuous, real-time monitoring of the prostate gland during external radiotherapy. Int J Radiat Oncol Biol Phys 2007 Mar 15, 67(4):1088-1098.
45. Langen K.M., Willoughby T.R., Meeks S.L., et al. Observations on real-time prostate gland motion using electromagnetic tracking. Int J Radiat Oncol Biol Phys 2008 Jul 15, 71(4):1084-1090.
46. UKCRN. The PACE Study (Prostate Advances in Comparative Evidence) 2014: Available from: . http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=12628.
47. Chen L.N., Suy S., Uhm S., et al. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience. Radiat Oncol 2013, 8:58.
48. Tree A.C., Ostler P., Hoskin P., et al. Prostate stereotactic body radiotherapy - first UK experience. Clin Oncol (R Coll Radiol) 2014 Sep 3, 26(12):757-761.
49. Spratt D.E., Pei X., Yamada J., Kollmeier M.A., Cox B., Zelefsky M.J. Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2013 Mar 1, 85(3):686-692.
50. Kim D.W., Cho L.C., Straka C., et al. Predictors of rectal tolerance observed in a dose-escalated phase 1-2 trial of stereotactic body radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 2014 Jul 1, 89(3):509-517.
51. Bhattasali O., Chen L.N., Woo J., et al. Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancer. Radiat Oncol 2014, 9:52.
52. Arscott W.T., Chen L.N., Wilson N., et al. Obstructive voiding symptoms following stereotactic body radiation therapy for prostate cancer. Radiat Oncol 2014, 9:163.
53. Rosewall T., Catton C., Currie G., et al. The relationship between external beam radiotherapy dose and chronic urinary dysfunction-a methodological critique. Radiother Oncol 2010 Oct, 97(1):40-47.
54. King C.R., Collins S., Fuller D., et al. Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: results from a multi-institutional consortium of prospective trials. Int J Radiat Oncol Biol Phys 2013 Dec 1, 87(5):939-945.
55. Keyes M., Miller S., Moravan V., et al. Urinary symptom flare in 712 125I prostate brachytherapy patients: long-term follow-up. Int J Radiat Oncol Biol Phys 2009 Nov 1, 75(3):649-655.
56. Sanda M.G., Dunn R.L., Michalski J., et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. NEngl J Med 2008 Mar 20, 358(12):1250-1261.
57. ISRCTN Phase III study of HYPOfractionated RadioTherapy of intermediate risk localised Prostate Cancer 2014, Available from:. http://www.controlled-trials.com/ISRCTN45905321.
58. Tree A. Successful patient acceptance of randomization within the pace study (Prostate Advances in Comparative Evidence). Int J Radiat Oncol Biol Phys 2013, 87(2S):S365.
59. US N Prostate accurately targeted radiotherapy investigation of overall treatment time (PATRIOT) 2014, Available from:. http://clinicaltrials.gov/show/NCT01423474.
60. NIH The SPARC trial: stereotactic prostate ablative radiotherapy using cyberknife 2014, Available from:. http://clinicaltrials.gov/show/NCT02145494.
61. Vavassori A., Jereczek-Fossa B.A., Beltramo G., et al. Image-guided robotic radiosurgery as salvage therapy for locally recurrent prostate cancer after external beam irradiation: retrospective feasibility study on six cases. Tumori 2010 Jan-Feb, 96(1):71-75.
62. Tree A, Jones C, Sohaib A, Khoo V, van As N. Prostate stereotactic body radiotherapy with simultaneous integrated boost: which is the best planning method? Radiat Oncol 2013;8(1):228.
63. Tree AC, Khoo VS, Eeles RA, et al. Stereotactic body radiotherapy for oligometastases. Lancet Oncol 2013 Jan;14(1):e28e37.
64. Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol 2011 Jun;8(6):378e382.
65. NICE. NICE guidelines [CG131] The diagnosis and management of colorectal cancer 2011: Available from: http://www. nice.org.uk/guidance/cg131/chapter/guidance.
66. Picchio M, Briganti A, Fanti S, et al. The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. Eur Urol 2011 Jan;59(1):51e60.
67. Mantel F, Flentje M, Guckenberger M. Stereotactic body radiation therapy in the re-irradiation situation e a review. Radiat Oncol 2013;8:7.
68. Jereczek-Fossa BA, Beltramo G, Fariselli L, et al. Robotic imageguided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer. Int J Radiat Oncol Biol Phys 2012 Feb 1;82(2):889e897.
69. Muacevic A, Kufeld M, Rist C. Safety and feasibility of imageguided robotic radiosurgery for patients with limited bone metastases of prostate cancer. Urol Oncol 2011 Apr 8;31(4):455e460.
70. Casamassima F, Masi L, Menichelli C, et al. Efficacy of eradicative radiotherapy for limited nodal metastases detected with choline PET scan in prostate cancer patients. Tumori 2011 Jan-Feb;97(1):49e55.
71. Decaestecker K, De Meerleer G, Lambert B, et al. Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence. Radiat Oncol 2014;9:135.
72. Isbarn H, Boccon-Gibod L, Carroll PR, et al. Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks. Eur Urol 2009 Jan;55(1):62e75.
73. Decaestecker K, De Meerleer G, Ameye F, et al. Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study profor a randomized phase II trial. BMC Cancer 2014 Sep 15;14(1):671.
74. van As NJ, Tree AC, Wells E, Petrucketvitch A, Khoo VS. Genitourinary toxicity from prostate SBRT e what are the predictive factors? ESTRO 2013-abstract presentation [serial on the Internet]. Available from: estro.ekonnect.co/ESTRO_790/ poster_58973/program.aspx; 2013.
75. Timmerman RD. An overview of hypofractionation and introduction to this issue of seminars in radiation oncology. Semin Radiat Oncol 2008 Oct;18(4):215e222.
76. Benedict SH, Yenice KM, Followill D, et al. Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys 2010 Aug;37(8):4078e4101.
77. Ahmed KA, Barney BM, Davis BJ, Park SS, Kwon ED, Olivier KR. Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer. Front Oncol 2012;2:215.